The code paves the way for reimbursement and expanded clinical use of AI-enabled heart disease detection.

Summary: Eko Health has been granted a Category III CPT code by the American Medical Association for its Sensora platform, an AI-enabled system for early heart disease detection. Effective July 1, 2025, the code facilitates reimbursement and broader clinical adoption. Sensora integrates FDA-cleared AI algorithms to identify structural heart murmurs, low ejection fraction, and arrhythmias in frontline care, enhancing the capabilities of Eko’s Core 500 digital stethoscope. Clinical studies have validated Sensora’s ability to improve heart disease detection, doubling sensitivity for structural heart disease and accurately identifying reduced ejection fraction in primary care.

Key Takeaways:

  1. CPT Code Enables Reimbursement: The newly issued Category III CPT code will support reimbursement for Sensora’s AI-based detection platform, increasing access to early heart disease diagnosis in clinical settings starting July 2025.
  2. Validated AI Algorithms: Sensora’s FDA-cleared algorithms improve detection of structural heart murmurs, arrhythmias, and low ejection fraction, with clinical studies showing significant accuracy improvements compared to traditional methods.
  3. Improved Accessibility: Sensora is designed to enhance frontline care, especially in underserved areas, by equipping clinicians with advanced tools to identify heart disease earlier, potentially reducing the need for specialist care.

Eko Health, a digital health company focused on applying artificial intelligence (AI) for the early detection of heart and lung diseases, announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association for its Sensor platform. 

The newly issued Category III CPT code will be effective on July 1, 2025, and paves the way for reimbursement and expanded clinical use of AI-enabled heart disease detection.

Sensora is an advanced early disease detection platform that includes US Food and Drug Administration-cleared AI algorithms that identify signs of structural heart murmurs, low ejection fraction, and arrhythmias, including AFib, in the front-line care setting. It integrates with Eko’s Core 500 digital stethoscope, which embeds advanced ECG technology in a tool that every provider is familiar with.

“The AMA’s creation of Category III CPT code for Eko’s AI disease detection algorithms is a major step in increasing access to early heart disease detection,” says Connor Landgraf, CEO of Eko Health, in a release. “This milestone will help enable clinicians to use powerful, validated tools to identify heart disease early, ultimately improving patient outcomes, especially in communities with limited access to specialist care.”

Clinically Validated Platform

Sensora’s AI algorithms, validated in clinical and real-world studies, assist clinicians in detecting cardiac disease signs often missed by standard care. An independent clinical validation published in Circulation showed that Eko’s structural heart murmur detection AI doubled sensitivity for structural heart disease compared to an analog stethoscope. 

Additionally, a Lancet Digital Health study involving over 1,000 patients confirmed Eko’s low ejection fraction AI accurately detects reduced ejection fraction in primary care, leading to its deployment in over 100 UK clinics by the NHS and Imperial College London.

Photo caption: Sensora

Photo credit: Eko Health